Jonathan C. Fox - Concepedia

Author

Jonathan C. Fox

Oregon Health & Science University ORCID

Also Known As

J Craig Fox, J. Craig Fox, Jonathan C. Fox, Jonathan Fox

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Oregon Health & Science University University College London Medical University of South Carolina Mayo Clinic Amyloidosis Foundation

About

Jonathan C. Fox is an author at Oregon Health & Science University specializing in cardiology, heart failure, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	101
2	Physiology	1	1	101
3	Cardiology	1	1	101
4	Heart Failure	1	1	101

Jonathan C. Fox

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy Carolyn Y. Ho, Sharlene M. Day, Euan A. Ashley, Circulation	2018	776
Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy Julian D. Gillmore, Daniel P. Judge, Francesco Cappelli, New England Journal of Medicine	2024	365
Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy Daniel P. Judge, Stephen B. Heitner, Rodney H. Falk, Journal of the American College of Cardiology	2019	244
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis Graham Lohrmann, Alexandra Pipilas, Roberta Mussinelli, Journal of Cardiac Failure Cardiac FunctionCardiomyopathyHeart FailureCardiac AmyloidosisPhysiology	2019	101
Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis Mark R. Miller, Arindom Pal, Wabel Albusairi, Journal of Medicinal Chemistry	2018	93
First‐in‐Human Study of AG10, a Novel, Oral, Specific, Selective, and Potent Transthyretin Stabilizer for the Treatment of Transthyretin Amyloidosis: A Phase 1 Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Healthy Adult Volunteers Jonathan C. Fox, Jennifer Hellawell, Satish Rao, Clinical Pharmacology in Drug Development	2019	60
Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial Daniel P. Judge, Julian D. Gillmore, Kevin Alexander, Circulation	2024	40
Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups David Rintell, Dena Heath, Florencia Braga Mendendez, Orphanet Journal of Rare Diseases	2021	30
Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid Cardiomyopathy Daniel P. Judge, Kevin Alexander, Francesco Cappelli, Journal of the American College of Cardiology	2025	29
Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy Mathew S. Maurer, Daniel P. Judge, Julian D. Gillmore, Journal of the American College of Cardiology	2025	20

Page 1